GILD  Gilead Sciences Inc.




Health Care


Biotechnology: Biological Products (No Diagnostic Substances)

Market Cap.


Vuru Grade


Current Price

-0.97 (-0.84%)

Growth Price

Overvalued by 15.58%

Stability Price

Overvalued by 66.52%

Company Metrics

  • 13.12 P/E
  • 6.2 P/S
  • 9.97 P/B
  • 8.77 EPS
  • 43.15% Cash ROIC
  • 1.76 Cash Ratio
  • 1.72 / 1.4% Dividend
  • 10.90M Avg. Vol.
  • 169.06B Market Cap.

Company Description

Gilead Sciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for the treatment of life threatening diseases worldwide. Its products include Atripla, Truvada, Viread, Emtriva for the treatment of human immunodeficiency virus infection in adults; Hepsera, an oral formulation for the treatment of chronic hepatitis B; AmBisome, a amph...

Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow


Here's What Gilead Sciences, Inc. And AbbVie Inc Latest Prescription Volumes ...
Bidness ETC - Jul 4, 2015
Gilead Sciences, Inc. (NASDAQ:GILD) saw a sharp decline in its HCV prescriptions during mid-June, as both of its HCV drugs, Harvoni and Sovaldi, witnessed a drop in their prescription volumes; however, the latest prescription data from Symphony ...
Japan's Ministry of Health, Labour and Welfare Approves Gilead's HarvoniĀ®, the ... - MarketWatch
Gilead's Harvoni, once-daily single tablet regimen for chronic hepatitis C ... -
Gilead Sciences, Inc. (GILD) Stock To Rise On NDA Submission For HIV Drug
Bidness ETC - Jul 2, 2015
Gilead Sciences, Inc. (NASDAQ:GILD) had been experiencing a severe blow to its stock's bull since June 25, 2015, but is finally on track to pull up the stock to growth.
Vetr Inc. Lowers Gilead Sciences to Hold (GILD) - WKRB News
Gilead Submits New Drug Application to US Food and Drug Administration for ... - MarketWatch
Should Gilead Sciences, Inc. (GILD) Worry About AbbVie 100% Cure Rate?
Bidness ETC - Jul 1, 2015
Last year, Gilead Sciences, Inc.'s (NASDAQ:GILD) unrivaled position as the leader in the HCV market was challenged when AbbVie Inc. (NYSE:ABBV) launched its HCV drug Viekira Pak in December, as a direct competitor to Gilead's blockbuster drug ...
Julian Robertson Really Likes Gilead Sciences - Barron's (blog)
Better Buy: Gilead Sciences Inc. or Celgene Corporation?
Motley Fool - Jun 18, 2015
Large-cap biotech companies Gilead Sciences (NASDAQ:GILD) and Celgene Corporation (NASDAQ:CELG) have made fortunes for their long-term investors.
Large Inflow of Money Witnessed in Gilead Sciences, Inc.
Money Flow Index - 1 hour ago
Gilead Sciences, Inc. (NASDAQ:GILD) dropped -0.84% or -0.97 points to trade at $115.04 per share. As per the latest trading data available, the net money flow stood at $112.89 million as the shares received $287.9 million in upticks and gave away $175 ...
Company Shares of Gilead Sciences, Inc. Drops by -3.73% - OTC Outlook
Today's Stocks: Gilead Sciences Inc. (NASDAQ:GILD), IRadimed Corporation ... - Stock Transcript
Biotech Short-Sellers Prefer Amgen To Gilead Sciences
Benzinga - Jun 27, 2015
Some of the biggest swings in short interest among the leading biotechs and emerging pharmaceuticals between the May 29 and June 15 settlement dates happened to Amgen, Inc. (NASDAQ: AMGN), Gilead Sciences, Inc. (NASDAQ: GILD) and Illumina, Inc.
Is Gilead Sciences Inc.'s Moat Filling Up With Sand?
Motley Fool - Jun 6, 2015
Gilead Sciences (NASDAQ:GILD) looks, at least superficially, like a classic value stock. The biotech's first-quarter revenues grew by a noteworthy 52% year over year, its rising free cash flows led to a nice bump in the share buyback program and the ...
Biotech Beat: MannKind Corporation (MNKD), Gilead Sciences, Inc. (GILD ...
Smarter Analyst - Jul 2, 2015
Well, the Greek Debt Crisis has come to a conclusion, a default; and US stocks seem to be back to normal. This leaves us with a bit of a mixed market in biotech today.
Gilead Sciences, Inc. (GILD) To Soar Higher: Oppenheimer
Bidness ETC - Jun 25, 2015
Gilead Sciences, Inc. (NASDAQ:GILD) has been soaring to great heights and is one of the hottest stock in the market.
Gilead Sciences Inc (GILD) Discloses SEC Form 4 Insider Selling : Paul ... - Money Flow Index
Gilead: Still My Next Apple (GILD) - Seeking Alpha
Gilead Sciences, Inc., Teva Pharmaceutical, AstraZeneca plc To Fuel Bidding ...
Bidness ETC - Jun 17, 2015
Receptos Inc (NASDAQ:RCPT) stock surged 4.63% during yesterday's trading as Wedbush analyst Liana Moussatos re-evaluated the company, following recent acquisition bids for it by pharmaceutical giants Gilead Sciences Inc. (NASDAQ:GILD), Teva ...
Wedbush Sees Bidding War For Receptos - Benzinga